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Abstract
Background: Overexpression of Metastasis-associated protein 1 (MTA1) in various cancer cells promotes tumor
invasion and migration and predicts cancer patients’ poor prognosis. The pilot RNA-Seq data from our laboratory
indicated that Epithelial cell adhesion molecule (EpCAM) was statistically reduced in MTA1-silencing cells. EpCAM
has been recognized as more than a mere cell adhesion molecule and recent findings have revealed its causal role
in mediating migratory and invasive capacity. Thus, this study was aimed to explore whether MTA1 was able to
upregulate EpCAM expression and, consequently, modulate its effects on invasion and migration of the lung cancer
cells as well as patients’ prognosis.
Methods: We checked the EpCAM expression by overexpressing or silencing MTA1 in lung cancer cells.
Furthermore, these lung cancer cells with stably overexpressed or silenced MTA1 were transfected with siEpCAM or
EpCAM-expressing plasmids and then subjected to western blot, invasion and migration assays. In addition, patients
(n = 118) with early-stage lung cancer were enrolled in this study to confirm the correlations between MTA1 and
EpCAM and pathoclinical parameters by using immunohistochemistry (IHC). All statistical analyses were performed
with SPSS 20.0 statistical software.
Results: MTA1 upregulated EpCAM expression in lung cancer cell lines, and EpCAM overexpression rescued the
inhibitory effects by silencing MTA1 on cell invasion and migration in vitro. What’s more, both MTA1 and EpCAM,
correlated to each other, were overexpressed in lung cancer tissues and significantly correlated with their clinical
stages, tumor diameters, lymph node metastasis. Multivariate analysis indicated that local advancement (p = 0.03),
MTA1 overexpression (p = 0.001) and EpCAM overexpression (p = 0.045) of the lung cancer tissues remained
significant in predicting unfavorable overall survival.
Conclusions: We revealed a new molecular mechanism of MTA1-mediated invasion and metastasis in lung cancer
through downstream target EpCAM, and interfering with EpCAM function may be a novel therapeutic strategy for
treatment of MTA1-overexpressing lung carcinoma.
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Background
Lung cancer is one of the most common and deadly tu-
mors in the world. From 1995 to 2009, 5-year overall
survival of lung cancer patients remains as low as 20 %
in developed and developing countries [1]. Clinical data
show that over 90 % of the deaths of patients with lung
cancer are direct or indirect consequence of cancer inva-
sion and metastasis [2].
Cancer metastasis is a multi-step process during
which cancer cells detach from the primary site,
penetrate into the circulation and colonize at distant
organs. Many studies have implicated Metastasis-
associated gene 1 (MTA1) as a pivotal regulator
during cancer metastasis. MTA1 is a subunit of the
nuclear remodeling and deacetylation (NuRD) com-
plex, which is over-activated in numerous malignant
cancers including lung, breast, and prostate cancers
[3–5]. MTA1 not only functions as a co-activator on
certain promoters, including β-catenin, BCAS3 and
STAT3, but also acts as a transcriptional co-repressor
of some target genes, such as E-cadherin [6]. Other
than NuRD complex, there are other mechanisms
adopted by MTA1 to exert a widespread regulation
on target molecules, such as acetylation modification.
Despite some targets that have been documented,
mechanistic understanding that how MTA1 induces
metastasis is still opaque in lung cancer.
Accumulating evidence suggests that MTA1 may pro-
mote tumorigenesis and tumor aggressiveness through
changing the expression of cell adhesion molecules.
Wang et al. identified that MTA1 can facilitate tumor in-
vasion by downregulating E-cadherin in esophageal
squamous cell carcinoma [4]. Also, RNA-seq of the
MTA1-silenced cells from our laboratory indicated that
Epithelial cell adhesion molecule (EpCAM) signifi-
cantly positively correlated with MTA1 (unpublished
results). EpCAM is a transmembrane glycoprotein,
which ranges its power from cell-to-cell adhesion to
cell proliferation, differentiation and migration [7].
Recently, a growing body of literatures suggests that
over-expressed EpCAM facilitates tumor invasion and
migration in breast cancer, colorectal cancer and thy-
roid cancers [8–10]. Based on the results described
above, we hypothesized that MTA1 may regulate
EpCAM to promote cancer invasion and migration
and, consequently, put its effects on the prognosis of
lung cancer patients.
In this study, we demonstrated that over-expression
of MTA1 induced EpCAM expression in human lung
cancer cell lines, leading to increased cell invasion
and migration. Expression of MTA1 and EpCAM is
strongly correlated to each other in lung cancer tis-
sues and high-level MTA1 and EpCAM predict
patients’ poor prognosis in multivariate analysis.
Methods
Cell lines and cell culture
Cancer cell lines A549 (adenocarcinoma cells), PC-9
(adenocarcinoma cells), and NCI-H446 (small cell lung
cancer cells) cells were maintained in our laboratory.
These cells were cultured in RPMI1640 medium supple-
mented with 10 % fetal bovine serum (FBS), penicillin
(100 U/ml), and streptomycin (100 mg/ml). These cells
were incubated at 37 °C and 5 % CO2 in a humidified
atmosphere.
Establishment of MTA1-knockdown and
MTA1-overexpressing cells
A549, PC-9, NCI-H446 cells were transfected with
Lenti-shMTA1, Lenti-MTA1, and Lenti-GFP (The three
vectors were purchased from Shanghai GenePharma Co,
Ltd. (Shanghai, China) at 40 MOI in 24-well culture
plate. Puromycin was used to screen the cells posi-
tively infected by the vectors. Finally, western blot
analysis was performed to examine the MTA1 expres-
sion level. The MTA1-over-expressing cells were
separately named as A549-MTA1, PC-9-MTA1, and NCI-
H446-MTA1 cells, and MTA1-silencing cells were re-
spectively named as A549-shMTA1, PC-9-shMTA1, and
NCI-H446-shMTA1 cells.
The siRNAs and plasmids transfection
MTA1-overexpressing or silenced cells were transfected
with EpCAM siRNA or EpCAM-expressing plasmid re-
spectively following the procedures stated in our previ-
ous publication [11]. The EpCAM small interfering RNA
(siRNA) and negative control were purchased from
Shanghai Gene Pharma Co. Ltd (Shanghai, China), and
the target sequence of EpCAM siRNA was 5′-UGCCAG
UGUACUUCAGUUGTT-3′. The pEnter-C-RFP-EpCAM
and pEnter-C-RFP plasmids were bought from ViGene
Co, Ltd. (Shandong, China). The GenBank accession
number was NM-002354. The MTA1-overexpressing cells
were transfected with EpCAM siRNA and NC siRNA, and
the MTA1-knocking down cells were transfected with
pEnter-C-RFP-EpCAM and pEnter-C-RFP for 24 h before
they were harvested for transfection efficiency assay and
biological assays.
Western blot analysis
Cells were lysed in RIPA buffer, and the protein concen-
tration was measured using the Bradford assay. The
whole protein samples were loaded onto 10 % SDS-
PAGE gels, and were transferred to a PVDF mem-
brane after electrophoresis. The membrane was
blocked with 5 % fat-free milk, and then incubated
with anti-MTA1 polyclonal antibody (ab71153; Abcam,
Cambridge, MA, USA), anti-EpCAM polyclonal antibody
(A1177; ABclonal, Boston, MA, USA) and anti-β-actin
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monoclonal antibody (A5316; Sigma-aldrich, St. Louis,
MO, USA) overnight at 4 °C, followed by peroxidase-
conjugated secondary antibody (1:5000) incubation for 1 h
at room temperature. Signals were visualized with ECL
and detected using LAS 4000 Imaging system (Fijifilm,
Tokyo, Japan).
Transwell invasion assay
Cells were seeded in serum-free medium in the upper
wells of transwell chambers with a 8-μm pore polycar-
bonate membrane (#3422; Corning Life Sciences, Tewks-
bury, MA, USA). The bottom wells were filled with fetal
bovine serum-completed medium (600 μL/well). After
cells were incubated for 48 h, the cells transmembraned
through and adhered to the bottom side of the mem-
brane were fixed and stained with 0.2 % crystal violet
dye. Then the cells were counted and averaged in the
randomly chosen five fields under microscope.
Wound healing assay
MTA1-knockdown cells transfected with pEnter-C-RFP-
EpCAM (or pEnter-C-RFP), and MTA1-overexpressing
cells transfected with siEpCAM (or negative control)
were cultured in 12-well plates. When the cells reached
80 % confluence, a sterilized pipette tip was used to
scratch a fine line with the same width on the cell layer.
The detached cells were washed off with PBS and the
remaining cells were cultured in complete medium. Pho-
tos were taken at 0, 12 and 24 h after the scratching.
Cells motility was presented by measuring the distance
of cells moving cross the scratching line under micros-
copy during the healing of the wound.
Patients and tissue microarray
The tissue microarray included 118 early stage lung car-
cinomas (stagesI, II, and IIIA) and 12 non-neoplastic
samples (who underwent surgical resection between
1998 and 2000 in the First Affiliated Hospital of China
Medical University). All the samples were fixed in for-
malin, embedded in paraffin, and sectioned at 4-μm for
immunohistochemistry and hematoxylin-eosin staining.
Patients with stage IIIB or IV lung cancers or incom-
plete clinical data were excluded from our analysis.
The diagnostic and histopathologic classification were
assessed according to World Health Organization
criteria [12]. The information of clinical pathological
variables was collected from the patients’ medical
records. This study was approved by the Ethics com-
mittee of the First Affiliated Hospital of China Med-
ical University, and informed consent has been signed
by every patient. The data of clinical pathological
variables were summarized in Table 1.
Immunohistochemical staining
The slides were baked at 60 °C for overnight, dewaxed
in xylene and rehydrated with gradient alcohol, then the
slides were boiled in citrate buffer for antigen retrieval.
Table 1 Correlation of MTA1 and EpCAM with clinicopathological
characteristics of lung cancer patients
Variables MTA1 EpCAM
Low High p Low High p
(N = 118) 53 65 51 67
Age (years)a
> = 57 (65) 28 37 0.66 26 39 0.44
<57 (53) 25 28 25 28
Gender
Male (90) 45 45 0.05 42 48 0.20
Female (28) 8 20 9 19
Histopathologic types
SCC (35) 21 14 0.02 19 16 0.02
ADC (46) 14 32 14 32
LCC (8) 3 5 5 3
SCLC (13) 8 5 9 4
Othersb (16) 6 10 4 12
Differentiation
Well (24) 15 9 0.12 11 13 0.85
Moderate (26) 9 17 10 16
Poorly (68) 29 39 30 38
Tumor diameter, cm
<3 (12) 9 3 0.04 6 6 0.78
3–5 (75) 34 41 33 42
>5 (31) 10 21 12 19
Local advance
T1,2 (94) 46 48 0.11 42 52 0.65
T3,4 (24) 7 17 9 15
Lymph node metastasis
N0 (53) 35 18 0.01 30 23 0.01
N1,2,3 (65) 18 47 21 44
Clinical stage
I/II (71) 43 28 0.01 37 34 0.02
IIIA (47) 10 37 14 33
Smoking status
No (45) 13 32 0.01 13 32 0.02
Yes (73) 40 33 38 35
Neoadjuvant treatment
NO (36) 21 15 0.07 19 17 0.20
Yes (82) 32 50 32 50
SCC squamous cell carcinoma, ADC adenocarcinoma, LCC Large cell carcinoma,
SCLC small cell lung cancer
aAge: The median age is 57 years old
bOthers: adenosquamous carcinoma and salivary-gland carcinoma
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Fig. 1 (See legend on next page.)
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:157 Page 4 of 10
After that, the slides were immersed in 3 % H2O2 to in-
activate endogenous peroxidase and blocked with goat
serum for 30 min. Next, the slides were incubated with
the primary monoclonal against MTA1 (ab71153; Abcam,
Cambridge, MA, USA) and EpCAM (A1177; ABclonal,
Boston, USA) diluted in 1:400 and 1:200 respectively in
PBS at 4 °C, followed by incubation with biotinylated-
second antibodies and streptavidin-peroxidase complex.
And protein staining signal was then observed with 3′-di-
aminobenzidine. Lastly, the slides were counterstained
with hematoxylin and mounted with neutral balsam. For a
negative control, the slides were incubated with PBS
instead of the primary antibody.
Scoring system and cutoff points
The IHC staining of MTA1 and EpCAM in the slides was
evaluated in a double-blinded manner by using a semi-
quantitative immune reactivity scoring system (IRS) for
both staining intensity (0: negative; 1: weak; 2: moder-
ate; 3: intense) and staining percentage of positively
stained cancer cells (0: none; 1: <10 %; 2: 10–50 %; 3:
51–80 %; 4: >80 %). The final staining scores ranged
from 0 to 12. A score >4 was defined as strong
MTA1 and EpCAM expression, and a score ≤4 was
defined as negative or weak expression of MTA1 and
EpCAM [13, 14].
Statistical analysis
All statistical analyses were performed using SPSS 20.0
software. A Student t-test or ANOVA test was used for
comparison of quantitative data. The χ2 test was used to
examine the correlation of MTA1 or EpCAM with
patients’ clinicopathological factors. The association
between MTA1 and EpCAM was analyzed by nonpara-
metric test (Spearman test). Survival rates were deter-
mined using the Kaplan-Meier method and were analyzed
using the log-rank test. The prognostic significance of
clinicopathological variables was also identified by univari-
ate and multivariate analysis using Cox proportional haz-
ard regression model. The statistical significance was
considered when the p value was <0.05.
Results
MTA1 upregulated EpCAM expression in lung cancer cells
To determine whether MTA1 can induce EpCAM
expression in lung cancer cells, Lenti-shMTA1 and
Lenti-MTA1 were used to stably infect the three lung
cancer lines (A549, PC-9 and NCI-H446). In this con-
text, overexpression of MTA1 in the three lung cancer
cell lines increased EpCAM expression at protein level
(Fig. 1a). Conversely, MTA1 knockdown in the three
lung cancer cell lines suppressed EpCAM protein
expression (Fig. 1a).
EpCAM induction was critical for MTA1-mediated cell
invasion and migration
MTA1 has been suggested to be involved in cell invasion
and migration. To confirm whether EpCAM mediates
the effects of MTA1 on cell invasion and migration, we
conducted the transwell invasion assay and wound heal-
ing assay in lung cancer cells. First, using A549 and
NCI-H446 cells infected with Lenti-shMTA1, Lenti-
MTA1, and Lenti-GFP, we performed transwell invasion
assay and found that MTA1-overexpressing cells were
significantly more invasive than control cells (155 ± 5.7
vs.105 ± 2.5 in A549 control cells, and 59 ± 1.4 vs. 36 ±
4.9 in NCI-H446 control cells, p < 0.05, Fig. 1b, c), and
MTA1-silenced cells was significantly impaired for their
invasion potential compared with negative control cells
(52 ± 5 vs.105 ± 2.5 in A549 control cells, and 15 ± 5 vs.
36 ± 4.9 in NCI-H446 control cells, p < 0.05, Fig. 1b, c).
Secondly, EpCAM siRNA and scramble siRNA were trans-
fected into MTA1-overexpressing cells (A549-MTA1 and
NCI-H446-MTA1), and pEnter-C-RFP-EpCAM (RFP-
(See figure on previous page.)
Fig. 1 MTA1 could upregulate EpCAM expression and promote invasion and migration via upregulation of EpCAM expression in lung cancer
cells. a Western blot analysis of the expression level of EpCAM in MTA1-overexpressing or MTA1-silencing cells. shNC: A549, PC-9, NCI-H446 cells
transfected with Lenti-shNC-GFP; shMTA1: A549, PC-9, NCI-H446 cells transfected with Lenti-shMTA1; NC: A549, PC-9, NCI-H446 cells transfected with
Lenti-NC-GFP. MTA1: A549, PC-9, NCI-H446 cells transfected with Lenti-MTA1. b Images of the transwell invasion assay in NC cells, MTA1-overepressed
cells transfected with Scramble siRNA or EpCAMsiRNA and MTA1-silenced cells transfected with vector control or EpCAM. c Quantitative analysis of
the number of invasion cells in the five groups of cells. The invaded cells were counted under × 200 magnification (five randomly selected fields).
First, the number of invasive shMTA1 cells was significantly reduced (*p < 0.05, shMTA1 vs. shNC), and the number of invasive MTA1 cells
was dramatically increased (*p < 0.05, MTA1 vs. NC). Second, invasive response of MTA1-overexpression cells was impaired significantly
after downregulatingEpCAM (*p < 0.05, EpCAMsiRNA vs. Scramble siRNA in MTA1-overexpression cells), and invasion could be rescued by
overexpressing EpCAM (*p< 0.05, EpCAM vs. Vector control in MTA1-silencing cells). d Representative images of the five cell groups in the wound healing
assay (magnification,×200). e Quantitative analysis of the migration ability of lung cancer cells. First, the MTA1-silencing could reduce cells motility when
compared with the negative controls cells (*p< 0.05, shMTA1 vs. shNC), and the MTA1-overexpression could increase cells motility when compared with
the negative controls cells (*p < 0.05, MTA1 vs. NC). Second, a knockdown of EpCAM expression in MTA1-overexpression cells could
dramatically attenuate cell migration (*p < 0.05, EpCAMsiRNA vs. Scramble siRNA in MTA1-overexpression cells), and the upregulation of EpCAM
in MTA1-silencing cells could regain cell migration (*p < 0.05, EpCAM vs. Vector control in MTA1-silencing cells). All experiments were repeated
three times
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EpCAM) and pEnter-C-RFP (RFP-NC) were transfected
into MTA1-knockdown cells (A549-shMTA1 and NCI-
H446-shMTA1) to see the mutual function rescue and
abolition effects . We found that invasion potential of
MTA1-overexpressing cells was decreased significantly
(155 ± 5.7 vs. 30 ± 3.8in A549-MTA1 control cells, and
59 ± 1.4 vs. 8 ± 1.7 in NCI-H446-MTA1 control cells,
p < 0.05, Fig. 1b, c) after reducing EpCAM level, and
the invasion ability in MTA1-silenced cells could be
rescued by overexpressing EpCAM (52 ± 5.0 vs. 123 ±
7.5in A549-shMTA1 cells, and 15 ± 5.0 vs. 97 ± 3.0in
NCI-H446-shMTA1 control cells, p < 0.05, Fig. 1b, c).
Third, we also performed wound healing assay using
the same cell set. Lenti-shMTA1 infection inhibited
Fig. 2 Expression of MTA1 and EpCAM in tissue microarray samples. a The immunohistochemistry results showed that MTA1 were overexpressed in
lung cancer tissues when compared with nonneoplastic tissues (*p< 0.05).b The immunohistochemistry results showed that EpCAM were overexpressed
in lung cancer tissues when compared with nonneoplastic tissues (*p < 0.05). c Representative images showing immunohistochemical expression in lung
cancer tissue specimens of MTA1 and EpCAM. Cases with strong and weak expression are represented. Original magnification, ×200
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cell migration, and the Lenti-MTA1 infection pro-
moted migration capacity of cancer cells when com-
pared with negative control cells (p < 0.05, Fig. 1d, e).
Similarily, reduced EpCAM expression in MTA1-
overexpressing cells dramatically impaired cell motil-
ity, and upregulation of EpCAM in MTA1-silencing
cells restored cell motility (p < 0.05, Fig. 1d, e). Taken
together, these results indicate that MTA1 signals
through EpCAM, at least in part, to stimulate the
invasion and migration abilities in lung cancer cells.
Expression of MTA1 and EpCAM in lung cancer and
non-neoplastic lung tissues
Of the 118 early stage lung cancer specimens, a high
level of MTA1 was detected in 65 (55.10 %) cancer
tissues, but only in 2 (16.70 %) of 12 non-neoplastic
lung tissues (Fig. 2a). The staining of MTA1 protein
exhibited both nuclear and cytoplasmic location in
the lung cancer tissues (Fig. 2c). For EpCAM protein,
it was overexpressed in 67 (56.8 %) cancer tissues,
but only in 1 (8.3 %) nonneoplastic lung tissues
(Fig. 2b). In positively stained cancer cells, EpCAM
was primarily localized on the cell membrane, with
occasional diffusion in cytoplasm (Fig. 2c).
Correlation of MTA1 expression with clinicopathological
variables
Table 1 showed the correlations of MTA1 expression
with the clinicopathological variables in lung cancer
cases. Significantly positive associations were identi-
fied between MTA1 expression and tumor diameter
(p = 0.04), lymph node metastasis (p < 0.01), clinical
stage (p < 0.01), but negative correlation was found
with smoking status (p = 0.01). A significant difference
was also proved for MTA1 overexpression in cancers
of various histopathological subtypes (p = 0.03). Fur-
ther analysis found that the frequency of MTA1 over-
expression was lower in squamous cell carcinoma
(SCC) and small cell lung cancer (SCLC) than in
adenocarcinoma (ADC). However, no significant cor-
relation was found between MTA1 expression and
age, gender, differentiation, local advance and neoad-
juvant treatment (p > 0.05).
Correlation of EpCAM expression with clinicopathological
variables
Table 1 also summarized the correlation of EpCAM ex-
pression and clinicopathological variables in lung cancer
cases. EpCAM overexpression was significantly posi-
tively associated with lymph node metastasis (p = 0.01),
clinical stage (p = 0.02), while negatively associated with
smoking status (p = 0.02). Similar to MTA1, a significant
difference in EpCAM expression was found between
various histopathological subtypes (p = 0.02). ADC had a
higher EpCAM overexpression rates compared to other
histopathological subtypes. But no significant correlation
were observed for EpCAM in relation to other clinico-
pathological characteristics.
Correlation between MTA1 and EpCAM
Figure 3 showed an correlation between MTA1 and
EpCAM by IHC staining in lung cancer tissues (p < 0.01,
spearman r = 0.588). In detail, high level MTA1 was
detected more frequently in those with EpCAM overex-
pression than in that with low EpCAM expression (45.8
versus 33.9 %, p < 0.01). We further analyzed the relation-
ship between MTA1 and EpCAM expression based on
histopathologic subtype stratification. As shown in Table 2,
familiar positive correlation between MTA1 staining
and EpCAM staining was found in ADC (p < 0.05), SCC
(p = 0.01), and SCLC (p = 0.01), while no correlation was
found in large cell carcinoma (LCC) (p > 0.05).
Univariate and multivariate survival analysis
According to the survival analysis, the mean overall
survival of patients with MTA1 and EpCAM overex-
pression was 33.8 months (95 % CI: 27.4–40.3) and
38.9 months (95 % CI: 31.6–46.2) respectively,
whereas those with low MTA1 and EpCAM expres-
sion was 76.6 months (95 % CI: 69.7–83.5) and
71.7 months (95 % CI: 64.1–79.3) separately (Fig. 4).
In univariate analysis, tumor differentiation (p = 0.008),
local progression (p = 0.001), lymph node metastasis (p <
0.001), clinical stage (p < 0.001), MTA1 and EpCAM high
expression (p < 0.001) significantly predicted unfavorable
overall survival (Table 3). Smoking status was not
Fig. 3 MTA1 expression positively correlates with EpCAM expression in
lung cancer patients. Statistics were calculated using Spearman testing.
*, p < 0.01
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identified as a prognostic factor in our data analysis
(p > 0.05), Table 3. Subsequently, all parameters with
significant prognostic power in univariate analysis
were included in multivariate analysis. As a result,
only local progression (p = 0.03, hazard ratio = 2.02),
differentiation (p = 0.03, hazard ratio = 1.52), MTA1
overexpression (p = 0.001, hazard ratio = 4.96) and
EpCAM overexpression (p = 0.045, hazard ratio =
1.92) remained significant as independent prognostic
factors, Table 3.
Discussion
Lung cancer is one of the most aggressive malignancy,
and metastasis is the leading cause of death lung cancer
patients’ death. Thus, elucidating the mechanisms of
lung cancer metastasis is crucial for improving the
patients’ prognosis. The results presented here proved
that MTA1 upregulated EpCAM in cancers for the first
time, and MTA1 overexpression promoted lung cancer
invasiveness in vitro. Furthermore, we demonstrated that
EpCAM promoted lung cancer cells invasion and migra-
tion, and the impaired tumor cell invasion and migration
abilities following MTA1-silenging can be rescued by
overexpressing EpCAM. In addition, a strong positive
correlation was observed between MTA1 and EpCAM
in IHC data, and MTA1 and EpCAM overexpression
predicted poor prognostic in lung cancer cases.
Our study has illustrated a possible correlation be-
tween MTA1 and EpCAM for the first time in ADC,
SCC, and SCLC. Further we first revealed a modulation
pattern between MTA1 and EpCAM. Some reports elu-
cidating EpCAM-regulated downstream signaling mole-
cules, such as E-cadherin and Wnt/β-catenin may help
explain our founding on MTA1 and EpCAM modulation
to promote tumor invasion and migration [8, 15–17]. To
verify that EpCAM expression is upregulated by MTA1
in vitro, gene transfection and RNA interference were
performed in lung cancer cells. We observed that
EpCAM was expressed at relatively low levels in
MTA1-knowdown cells, while its expression was up-
regulated in MTA1-overexpressing cells. Further, the
suppressed metastasis ability was rescued when
EpCAM was transfected to the MTA1-silenced cells,
while the increased metastasis potential was inhibited
when EpCAM was silenced in MTA1-overexpressing
cells. These data suggested that EpCAM is a down-
stream molecule of MTA1 in lung cancer. Although
NuRD has been reported to be a key effector in
MTA1-regulated gene expression profile, we did not
see modulation of EpCAM through NuRD complex
(data not shown). There may be other mechanisms
involved in the network.
MTA1 is known to promote the invasion and mi-
gration in a variety of cancer. In our study, we also
demonstrated that MTA1 protein was significantly
Fig. 4 Kaplan-Meier analysis of overall survival in all lung cancer patients. a Patients with MTA1 overexpression had a poorer prognosis. b Patients
with EpCAM overexpression had a poorer prognosis. The log-rank test was used to calculate p value. *, p < 0.01




Squamous cell carcinoma EpCAM Low 17 19 0.01
High 5 16
Adenocarcinoma EpCAM Low 9 5 0.00
High 5 27
Large cell carcinoma EpCAM Low 2 3 0.71
High 1 2
Small cell carcinoma EpCAM Low 8 1 0.01
High 0 4
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higher in lung cancer tissues (including small cell
lung cancer) than in normal lung tissues. In addition,
it was significantly positively associated with tumor
diameter, clinical stage, and lymph node metastasis,
suggesting MTA1 protein is engaged in the progres-
sion and aggression of lung cancer. As reported by
Yu. And Li et al., our results also revealed that
MTA1 overexpression independently and significantly
predicts poor overall survival of the patients with
early stage lung cancer [6, 18].
To date, EpCAM overexpression has been indicated
to be able to predict poor prognosis of the patients
with renal cancer [19], breast cancer [8], prostate can-
cer [20], ovarian cancer [21] and hypopharyngeal can-
cer [22], while its prognostic value was controversial
in lung cancer. Thus, we also evaluated the correl-
ation of EpCAM level with clinicopathological param-
eters and patients’ prognosis in tumor samples from
lung cancer patients. Consistent with our study, re-
ports have showed that clinical stage and lymph node
metastasis of cancer patients were correlated with
EpCAM expression, and EpCAM independently pre-
dicted poor overall survival in multivariate analysis
[23, 24]. Contrary to our study, Pak et al. showed that
lymph node metastasis was not association with
EpCAM overexpression [25], what’s more, Gold et al.
reported that EpCAM overexpression was a signifi-
cant predictor for favorable overall survival and dis-
ease free survival [26], and even Pak et al. indicated
that EpCAM overexpression was not correlated with
overall survival in ADC and SCC. The difference in
the reported association between EpCAM and pa-
tients’ prognosis may be caused by heterogeneity of
the patient population recruited in these sutdies. For
example, a collective patients’ comparison between
Gold’s and ours have shown some diversity in clinical
stage (16.5 versus 39.8 % in IIIA stages) and histo-
pathologic type (61.4 versus 39.0 % in ADC, and 34.1
versus 29.6 % in SCC).
Conclusion
In summary, our results provided a new insight into
MTA1-mediated invasion and migration by enhancing
EpCAM level in lung cancer. And MTA1 and EpCAM
overexpression independently predicted unfavorable
prognosis in our 118 lung cancer patients. Therefore, we
hope that the results presented here may be helpful in
the development of anti-metastatic strategies to poten-
tially target the MTA1 alone or combined with EpCAM
to inhibit the metastasis of lung cancer.
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